Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 124 | 2023 | 16678 | 3.780 |
Why?
|
Anti-HIV Agents | 52 | 2020 | 4250 | 2.410 |
Why?
|
HIV | 17 | 2020 | 1600 | 2.040 |
Why?
|
HIV-1 | 60 | 2020 | 6934 | 1.870 |
Why?
|
Models, Statistical | 30 | 2023 | 5100 | 1.810 |
Why?
|
Drug Resistance, Viral | 18 | 2012 | 820 | 1.800 |
Why?
|
Antiretroviral Therapy, Highly Active | 25 | 2023 | 1872 | 1.720 |
Why?
|
Randomized Controlled Trials as Topic | 26 | 2020 | 9941 | 1.560 |
Why?
|
Bayes Theorem | 10 | 2023 | 2303 | 1.520 |
Why?
|
Biostatistics | 7 | 2017 | 160 | 1.520 |
Why?
|
Data Interpretation, Statistical | 19 | 2017 | 2714 | 1.480 |
Why?
|
Acquired Immunodeficiency Syndrome | 39 | 2012 | 2231 | 1.240 |
Why?
|
Viral Load | 26 | 2020 | 3292 | 1.150 |
Why?
|
Likelihood Functions | 12 | 2020 | 1003 | 1.100 |
Why?
|
Computer Simulation | 22 | 2017 | 6191 | 0.990 |
Why?
|
CD4 Lymphocyte Count | 36 | 2018 | 2557 | 0.970 |
Why?
|
Models, Genetic | 9 | 2011 | 3493 | 0.930 |
Why?
|
Zidovudine | 18 | 2015 | 620 | 0.920 |
Why?
|
Cluster Analysis | 11 | 2019 | 2713 | 0.910 |
Why?
|
Anti-Retroviral Agents | 13 | 2019 | 1712 | 0.900 |
Why?
|
Botswana | 20 | 2020 | 1040 | 0.890 |
Why?
|
Genetic Linkage | 3 | 2019 | 2422 | 0.890 |
Why?
|
Clinical Trials as Topic | 24 | 2020 | 7901 | 0.820 |
Why?
|
RNA, Viral | 31 | 2020 | 2899 | 0.800 |
Why?
|
Research Design | 15 | 2020 | 5979 | 0.800 |
Why?
|
Sample Size | 7 | 2017 | 844 | 0.720 |
Why?
|
Markov Chains | 6 | 2013 | 969 | 0.660 |
Why?
|
Sexually Transmitted Diseases | 2 | 2023 | 622 | 0.660 |
Why?
|
Indinavir | 6 | 2008 | 74 | 0.660 |
Why?
|
Sexual Partners | 5 | 2018 | 730 | 0.610 |
Why?
|
Communicable Diseases | 2 | 2023 | 878 | 0.580 |
Why?
|
Clinical Protocols | 2 | 2020 | 1459 | 0.570 |
Why?
|
Reverse Transcriptase Inhibitors | 12 | 2010 | 615 | 0.570 |
Why?
|
Speech Perception | 4 | 2022 | 489 | 0.550 |
Why?
|
Disease Outbreaks | 6 | 2021 | 1768 | 0.530 |
Why?
|
Cochlea | 5 | 2023 | 828 | 0.500 |
Why?
|
Benzoxazines | 8 | 2012 | 301 | 0.460 |
Why?
|
HIV Protease Inhibitors | 6 | 2014 | 430 | 0.450 |
Why?
|
Humans | 193 | 2023 | 742088 | 0.450 |
Why?
|
Circumcision, Male | 3 | 2020 | 150 | 0.450 |
Why?
|
Didanosine | 10 | 2010 | 153 | 0.440 |
Why?
|
Dideoxynucleosides | 4 | 2012 | 122 | 0.430 |
Why?
|
Presbycusis | 3 | 2022 | 42 | 0.430 |
Why?
|
Sexual Behavior | 6 | 2017 | 2050 | 0.430 |
Why?
|
Publishing | 1 | 2020 | 833 | 0.430 |
Why?
|
Phylogeny | 7 | 2020 | 2797 | 0.430 |
Why?
|
Longitudinal Studies | 15 | 2020 | 13921 | 0.420 |
Why?
|
Homosexuality, Male | 2 | 2019 | 1238 | 0.410 |
Why?
|
Mycobacterium tuberculosis | 3 | 2013 | 1825 | 0.410 |
Why?
|
Organ Transplantation | 1 | 2022 | 1135 | 0.400 |
Why?
|
AIDS Vaccines | 5 | 2012 | 938 | 0.400 |
Why?
|
Emergency Service, Hospital | 7 | 2011 | 7645 | 0.390 |
Why?
|
Auditory Threshold | 6 | 2023 | 364 | 0.380 |
Why?
|
AIDS Serodiagnosis | 5 | 2016 | 184 | 0.380 |
Why?
|
Drug Resistance, Multiple, Viral | 3 | 2007 | 52 | 0.380 |
Why?
|
Cochlear Nerve | 3 | 2021 | 197 | 0.370 |
Why?
|
Models, Theoretical | 2 | 2020 | 3584 | 0.370 |
Why?
|
HIV Envelope Protein gp120 | 2 | 2014 | 952 | 0.360 |
Why?
|
Hair Cells, Auditory, Outer | 2 | 2021 | 98 | 0.360 |
Why?
|
Mass Screening | 13 | 2020 | 5238 | 0.350 |
Why?
|
Models, Biological | 7 | 2016 | 9581 | 0.350 |
Why?
|
Models, Immunological | 2 | 2010 | 527 | 0.340 |
Why?
|
HIV Protease | 2 | 2008 | 96 | 0.340 |
Why?
|
Public Health | 3 | 2019 | 2594 | 0.330 |
Why?
|
Genotype | 18 | 2020 | 12946 | 0.330 |
Why?
|
Pregnancy Outcome | 1 | 2019 | 2795 | 0.320 |
Why?
|
Noise | 5 | 2021 | 279 | 0.320 |
Why?
|
Statistics, Nonparametric | 5 | 2012 | 2885 | 0.320 |
Why?
|
Hearing | 3 | 2023 | 479 | 0.320 |
Why?
|
Computer-Assisted Instruction | 1 | 2011 | 365 | 0.310 |
Why?
|
Algorithms | 14 | 2020 | 13853 | 0.310 |
Why?
|
Health Services Research | 2 | 2018 | 1834 | 0.300 |
Why?
|
Communicable Disease Control | 2 | 2014 | 854 | 0.300 |
Why?
|
Multivariate Analysis | 7 | 2014 | 12242 | 0.290 |
Why?
|
Hair Cells, Auditory, Inner | 4 | 2021 | 191 | 0.280 |
Why?
|
Genome, Viral | 3 | 2020 | 667 | 0.280 |
Why?
|
Communication | 1 | 2020 | 3728 | 0.280 |
Why?
|
HIV Core Protein p24 | 4 | 1996 | 256 | 0.270 |
Why?
|
Statistics as Topic | 2 | 2019 | 2372 | 0.270 |
Why?
|
HIV Seropositivity | 9 | 2016 | 970 | 0.270 |
Why?
|
Mutation | 12 | 2011 | 29717 | 0.270 |
Why?
|
Survival Analysis | 8 | 2012 | 10248 | 0.260 |
Why?
|
Counseling | 3 | 2015 | 1521 | 0.260 |
Why?
|
Proportional Hazards Models | 12 | 2019 | 12344 | 0.260 |
Why?
|
Nerve Degeneration | 2 | 2021 | 748 | 0.260 |
Why?
|
Patient Acceptance of Health Care | 5 | 2011 | 3014 | 0.260 |
Why?
|
Risk-Taking | 2 | 2011 | 986 | 0.250 |
Why?
|
Ethics, Research | 1 | 2006 | 190 | 0.250 |
Why?
|
Blood Component Removal | 1 | 2005 | 125 | 0.250 |
Why?
|
Treatment Outcome | 31 | 2020 | 62966 | 0.250 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2013 | 910 | 0.250 |
Why?
|
Drug Utilization | 1 | 2011 | 1181 | 0.250 |
Why?
|
Antitubercular Agents | 1 | 2013 | 1319 | 0.250 |
Why?
|
Sampling Studies | 4 | 2014 | 623 | 0.240 |
Why?
|
Hearing Loss, Sensorineural | 2 | 2022 | 770 | 0.240 |
Why?
|
Biometry | 6 | 2012 | 558 | 0.240 |
Why?
|
Vestibulocochlear Nerve Diseases | 1 | 2023 | 31 | 0.230 |
Why?
|
Drug Therapy, Combination | 21 | 2012 | 6483 | 0.230 |
Why?
|
Audiometry | 2 | 2021 | 242 | 0.230 |
Why?
|
Adult | 76 | 2023 | 213712 | 0.230 |
Why?
|
Male | 89 | 2021 | 349538 | 0.220 |
Why?
|
Endpoint Determination | 2 | 2019 | 600 | 0.210 |
Why?
|
Hearing Loss, Noise-Induced | 2 | 2021 | 144 | 0.210 |
Why?
|
AIDS Dementia Complex | 3 | 2013 | 152 | 0.210 |
Why?
|
Female | 82 | 2021 | 379592 | 0.210 |
Why?
|
Gene Dosage | 1 | 2007 | 1251 | 0.210 |
Why?
|
CD4-Positive T-Lymphocytes | 5 | 2017 | 4379 | 0.210 |
Why?
|
Comprehension | 1 | 2007 | 608 | 0.210 |
Why?
|
Salvage Therapy | 3 | 2010 | 1269 | 0.200 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 2 | 2020 | 249 | 0.200 |
Why?
|
AIDS-Related Complex | 4 | 1995 | 111 | 0.200 |
Why?
|
Thailand | 5 | 2015 | 296 | 0.190 |
Why?
|
Tinnitus | 1 | 2023 | 195 | 0.190 |
Why?
|
Nonlinear Dynamics | 2 | 2020 | 502 | 0.190 |
Why?
|
Cell Separation | 2 | 2009 | 1749 | 0.190 |
Why?
|
Meniere Disease | 1 | 2022 | 161 | 0.190 |
Why?
|
Alkynes | 8 | 2012 | 306 | 0.190 |
Why?
|
Stria Vascularis | 1 | 2020 | 31 | 0.190 |
Why?
|
Bisoprolol | 1 | 2000 | 8 | 0.190 |
Why?
|
Disease Transmission, Infectious | 2 | 2018 | 546 | 0.190 |
Why?
|
Nelfinavir | 6 | 2005 | 68 | 0.180 |
Why?
|
Haplotypes | 1 | 2007 | 2781 | 0.180 |
Why?
|
Cyclopropanes | 8 | 2012 | 416 | 0.180 |
Why?
|
Perceptual Masking | 1 | 2020 | 94 | 0.180 |
Why?
|
DNA, Viral | 4 | 2013 | 2224 | 0.180 |
Why?
|
Drug Resistance, Microbial | 7 | 2004 | 860 | 0.170 |
Why?
|
Speech Intelligibility | 1 | 2020 | 81 | 0.170 |
Why?
|
Biotechnology | 1 | 2001 | 278 | 0.170 |
Why?
|
Leukocyte Count | 2 | 1993 | 1583 | 0.170 |
Why?
|
Causality | 2 | 2018 | 1265 | 0.170 |
Why?
|
Information Dissemination | 1 | 2007 | 1100 | 0.170 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2012 | 839 | 0.160 |
Why?
|
Acidosis, Lactic | 2 | 2012 | 142 | 0.160 |
Why?
|
Adenine | 4 | 2011 | 936 | 0.160 |
Why?
|
Tuberculosis | 1 | 2011 | 1904 | 0.160 |
Why?
|
Polymorphism, Genetic | 2 | 2008 | 4328 | 0.160 |
Why?
|
New England | 3 | 2010 | 1021 | 0.160 |
Why?
|
Peripheral Nervous System Diseases | 2 | 2015 | 700 | 0.160 |
Why?
|
Geography | 1 | 2020 | 669 | 0.160 |
Why?
|
Young Adult | 20 | 2021 | 56350 | 0.160 |
Why?
|
Treatment Failure | 10 | 2010 | 2615 | 0.150 |
Why?
|
Adolescent | 27 | 2021 | 85649 | 0.150 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2018 | 3915 | 0.150 |
Why?
|
Hair Cells, Auditory | 1 | 2020 | 361 | 0.150 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 1998 | 194 | 0.150 |
Why?
|
Middle Aged | 44 | 2021 | 213127 | 0.150 |
Why?
|
Cimetidine | 1 | 1996 | 78 | 0.150 |
Why?
|
Epidemics | 2 | 2015 | 521 | 0.150 |
Why?
|
Chicago | 1 | 2017 | 238 | 0.140 |
Why?
|
Ebola Vaccines | 1 | 2016 | 24 | 0.140 |
Why?
|
Time Factors | 23 | 2023 | 40054 | 0.140 |
Why?
|
Condoms | 2 | 2016 | 323 | 0.140 |
Why?
|
Africa South of the Sahara | 2 | 2017 | 724 | 0.140 |
Why?
|
Incidence | 11 | 2020 | 20928 | 0.140 |
Why?
|
Analysis of Variance | 4 | 2012 | 6365 | 0.140 |
Why?
|
Universities | 1 | 2021 | 953 | 0.140 |
Why?
|
Serologic Tests | 1 | 2018 | 374 | 0.130 |
Why?
|
ROC Curve | 4 | 2013 | 3528 | 0.130 |
Why?
|
Double-Blind Method | 16 | 2020 | 12017 | 0.130 |
Why?
|
Mathematical Concepts | 1 | 2015 | 63 | 0.130 |
Why?
|
Prevalence | 8 | 2020 | 15194 | 0.130 |
Why?
|
Educational Status | 2 | 2017 | 2533 | 0.130 |
Why?
|
Molecular Epidemiology | 2 | 2015 | 468 | 0.130 |
Why?
|
Patient Education as Topic | 3 | 2011 | 2275 | 0.130 |
Why?
|
Probability | 4 | 2014 | 2502 | 0.120 |
Why?
|
Homosexuality | 4 | 1994 | 264 | 0.120 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2009 | 654 | 0.120 |
Why?
|
Computational Biology | 3 | 2015 | 3518 | 0.120 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2000 | 1239 | 0.120 |
Why?
|
Deafness | 1 | 2018 | 461 | 0.120 |
Why?
|
South Africa | 5 | 2018 | 1728 | 0.120 |
Why?
|
Nevirapine | 2 | 2012 | 267 | 0.120 |
Why?
|
Antiviral Agents | 5 | 2001 | 2978 | 0.110 |
Why?
|
Trail Making Test | 1 | 2013 | 57 | 0.110 |
Why?
|
Linear Models | 4 | 2017 | 5948 | 0.110 |
Why?
|
Video Recording | 2 | 2008 | 944 | 0.110 |
Why?
|
Vitamin D | 2 | 2020 | 3211 | 0.110 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7153 | 0.110 |
Why?
|
Oxazines | 5 | 2005 | 298 | 0.110 |
Why?
|
Chemoprevention | 2 | 2016 | 319 | 0.110 |
Why?
|
Family Health | 1 | 2018 | 1282 | 0.110 |
Why?
|
Viremia | 4 | 2009 | 735 | 0.110 |
Why?
|
Action Potentials | 1 | 2020 | 1814 | 0.110 |
Why?
|
Emergencies | 1 | 2019 | 1164 | 0.110 |
Why?
|
Cooperative Behavior | 1 | 2020 | 1503 | 0.110 |
Why?
|
Risk | 9 | 2016 | 9679 | 0.110 |
Why?
|
Urban Population | 3 | 2010 | 2018 | 0.110 |
Why?
|
Microbial Sensitivity Tests | 2 | 2013 | 1871 | 0.100 |
Why?
|
Population Surveillance | 4 | 2015 | 2616 | 0.100 |
Why?
|
Drug Monitoring | 2 | 1998 | 956 | 0.100 |
Why?
|
Regression Analysis | 9 | 2013 | 6452 | 0.100 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2016 | 428 | 0.100 |
Why?
|
Vascular Surgical Procedures | 1 | 2000 | 1473 | 0.100 |
Why?
|
Predictive Value of Tests | 9 | 2012 | 15056 | 0.100 |
Why?
|
Polyneuropathies | 1 | 2012 | 139 | 0.090 |
Why?
|
Deoxycytidine | 2 | 2011 | 824 | 0.090 |
Why?
|
Vaccines | 1 | 2019 | 817 | 0.090 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2017 | 4438 | 0.090 |
Why?
|
Sensory Receptor Cells | 1 | 2015 | 487 | 0.090 |
Why?
|
Logistic Models | 4 | 2011 | 13403 | 0.090 |
Why?
|
Rural Population | 5 | 2019 | 2207 | 0.090 |
Why?
|
Rhode Island | 2 | 2008 | 347 | 0.090 |
Why?
|
Synapses | 1 | 2019 | 1724 | 0.090 |
Why?
|
Pregnancy | 6 | 2019 | 29087 | 0.090 |
Why?
|
HIV Seroprevalence | 2 | 1992 | 86 | 0.090 |
Why?
|
Drug Users | 1 | 2011 | 131 | 0.090 |
Why?
|
Ritonavir | 1 | 2011 | 322 | 0.090 |
Why?
|
Stavudine | 4 | 2015 | 85 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2013 | 19862 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3256 | 0.090 |
Why?
|
Senegal | 1 | 2010 | 294 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2000 | 2145 | 0.090 |
Why?
|
Fatty Acids | 1 | 2017 | 1806 | 0.080 |
Why?
|
Sexually Transmitted Diseases, Viral | 1 | 1989 | 40 | 0.080 |
Why?
|
Primary Prevention | 1 | 2016 | 1166 | 0.080 |
Why?
|
Indoles | 1 | 2017 | 1834 | 0.080 |
Why?
|
Cognition Disorders | 2 | 2013 | 4030 | 0.080 |
Why?
|
Drug Administration Schedule | 4 | 2012 | 4929 | 0.080 |
Why?
|
Monocytes | 3 | 2013 | 2593 | 0.080 |
Why?
|
Risk Assessment | 4 | 2017 | 23320 | 0.080 |
Why?
|
Risk Factors | 15 | 2020 | 72145 | 0.080 |
Why?
|
Neurotoxicity Syndromes | 1 | 2012 | 290 | 0.080 |
Why?
|
Heterosexuality | 2 | 2016 | 271 | 0.080 |
Why?
|
Prenatal Care | 1 | 2015 | 1088 | 0.080 |
Why?
|
Cross Infection | 1 | 2017 | 1413 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2020 | 3294 | 0.080 |
Why?
|
Thymidine | 1 | 2007 | 309 | 0.070 |
Why?
|
Databases, Factual | 2 | 2013 | 7716 | 0.070 |
Why?
|
Computers | 1 | 2009 | 611 | 0.070 |
Why?
|
Lactic Acid | 1 | 2012 | 1132 | 0.070 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2011 | 563 | 0.070 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2007 | 248 | 0.070 |
Why?
|
Internationality | 1 | 2012 | 1002 | 0.070 |
Why?
|
Behavior Therapy | 1 | 2012 | 866 | 0.070 |
Why?
|
Cohort Studies | 10 | 2020 | 40450 | 0.070 |
Why?
|
Feedback | 1 | 2009 | 793 | 0.070 |
Why?
|
Centrifugation | 1 | 2005 | 122 | 0.070 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1411 | 0.070 |
Why?
|
Viruses | 1 | 2009 | 374 | 0.070 |
Why?
|
Disease Progression | 8 | 2011 | 13256 | 0.070 |
Why?
|
Genomics | 1 | 2001 | 5692 | 0.070 |
Why?
|
Hemorheology | 1 | 2005 | 145 | 0.070 |
Why?
|
Sequence Analysis, DNA | 2 | 2015 | 4801 | 0.070 |
Why?
|
Demography | 5 | 2010 | 1650 | 0.070 |
Why?
|
Neutropenia | 1 | 2010 | 891 | 0.070 |
Why?
|
Lamivudine | 3 | 2003 | 342 | 0.060 |
Why?
|
United States | 15 | 2019 | 69693 | 0.060 |
Why?
|
Drug Discovery | 1 | 2013 | 1057 | 0.060 |
Why?
|
Aging | 2 | 2021 | 8626 | 0.060 |
Why?
|
Epidemiology | 1 | 1988 | 287 | 0.060 |
Why?
|
Molecular Sequence Data | 4 | 2014 | 18112 | 0.060 |
Why?
|
Biophysical Phenomena | 1 | 2005 | 327 | 0.060 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 1123 | 0.060 |
Why?
|
Patient Compliance | 3 | 2010 | 2680 | 0.060 |
Why?
|
Lipase | 1 | 2007 | 315 | 0.060 |
Why?
|
Saquinavir | 2 | 2002 | 28 | 0.060 |
Why?
|
Biophysics | 1 | 2005 | 383 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2010 | 968 | 0.060 |
Why?
|
International Cooperation | 1 | 2011 | 1421 | 0.060 |
Why?
|
Area Under Curve | 1 | 2008 | 1653 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2011 | 780 | 0.060 |
Why?
|
Vascular Diseases | 1 | 2011 | 1155 | 0.060 |
Why?
|
Cyclohexanes | 1 | 2023 | 152 | 0.060 |
Why?
|
Lymphocyte Activation | 4 | 2017 | 5519 | 0.060 |
Why?
|
Hearing Loss | 2 | 2020 | 765 | 0.050 |
Why?
|
Thrombocytopenia | 1 | 2010 | 1171 | 0.050 |
Why?
|
Phenotype | 5 | 2003 | 16331 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
Professional-Patient Relations | 1 | 2007 | 736 | 0.050 |
Why?
|
Family Characteristics | 2 | 2018 | 999 | 0.050 |
Why?
|
Basic Reproduction Number | 1 | 2021 | 31 | 0.050 |
Why?
|
Uncertainty | 1 | 2007 | 725 | 0.050 |
Why?
|
Retrospective Studies | 11 | 2022 | 77098 | 0.050 |
Why?
|
Audiometry, Pure-Tone | 1 | 2022 | 204 | 0.050 |
Why?
|
Medical Oncology | 1 | 2013 | 2235 | 0.050 |
Why?
|
Acyclovir | 1 | 2002 | 272 | 0.050 |
Why?
|
Evolution, Molecular | 2 | 2007 | 1937 | 0.050 |
Why?
|
Hearing Loss, Conductive | 1 | 2022 | 158 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2003 | 1661 | 0.050 |
Why?
|
Inhibitory Concentration 50 | 1 | 2002 | 459 | 0.050 |
Why?
|
Anemia | 1 | 2010 | 1499 | 0.050 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2001 | 170 | 0.050 |
Why?
|
Hemophilia A | 3 | 1995 | 351 | 0.050 |
Why?
|
Bisexuality | 1 | 2003 | 270 | 0.050 |
Why?
|
Observer Variation | 1 | 2007 | 2593 | 0.050 |
Why?
|
Audiometry, Evoked Response | 1 | 2020 | 44 | 0.050 |
Why?
|
Amino Acid Sequence | 2 | 2003 | 13814 | 0.050 |
Why?
|
Valine | 1 | 2002 | 413 | 0.050 |
Why?
|
Los Angeles | 1 | 2020 | 238 | 0.050 |
Why?
|
Mathematics | 2 | 1994 | 727 | 0.050 |
Why?
|
Survival Rate | 1 | 1994 | 12773 | 0.050 |
Why?
|
Reflex, Acoustic | 1 | 2020 | 33 | 0.050 |
Why?
|
Odds Ratio | 2 | 2010 | 9846 | 0.050 |
Why?
|
Cholesterol, HDL | 1 | 2007 | 1813 | 0.050 |
Why?
|
Follow-Up Studies | 9 | 2012 | 39004 | 0.040 |
Why?
|
Monte Carlo Method | 1 | 2005 | 1254 | 0.040 |
Why?
|
Acoustic Impedance Tests | 1 | 2020 | 109 | 0.040 |
Why?
|
Age Distribution | 2 | 2018 | 2900 | 0.040 |
Why?
|
Health Surveys | 1 | 2010 | 4030 | 0.040 |
Why?
|
HIV Envelope Protein gp160 | 1 | 1999 | 99 | 0.040 |
Why?
|
Cross-Sectional Studies | 6 | 2020 | 24913 | 0.040 |
Why?
|
Dyslipidemias | 1 | 2007 | 848 | 0.040 |
Why?
|
Otoacoustic Emissions, Spontaneous | 1 | 2020 | 136 | 0.040 |
Why?
|
Hepacivirus | 1 | 2006 | 1372 | 0.040 |
Why?
|
Mice, Inbred CBA | 1 | 2019 | 447 | 0.040 |
Why?
|
Auditory Perception | 1 | 2023 | 568 | 0.040 |
Why?
|
Meta-Analysis as Topic | 2 | 2001 | 1342 | 0.040 |
Why?
|
Multigene Family | 1 | 2002 | 1102 | 0.040 |
Why?
|
Auditory Pathways | 1 | 2020 | 233 | 0.040 |
Why?
|
Hepatitis C, Chronic | 1 | 2006 | 1027 | 0.040 |
Why?
|
Sex Factors | 5 | 2019 | 10392 | 0.040 |
Why?
|
Half-Life | 1 | 1999 | 658 | 0.040 |
Why?
|
Hearing Tests | 1 | 2018 | 122 | 0.040 |
Why?
|
Macrophages | 1 | 2012 | 5655 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2002 | 730 | 0.040 |
Why?
|
Genetic Variation | 2 | 2010 | 6540 | 0.040 |
Why?
|
Prognosis | 4 | 2017 | 29010 | 0.040 |
Why?
|
Triazoles | 1 | 2023 | 907 | 0.040 |
Why?
|
Prospective Studies | 6 | 2013 | 53187 | 0.040 |
Why?
|
Ear, Middle | 1 | 2020 | 332 | 0.040 |
Why?
|
Inflammation | 1 | 2017 | 10578 | 0.040 |
Why?
|
Plasma | 2 | 2017 | 575 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2001 | 790 | 0.040 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2008 | 2026 | 0.040 |
Why?
|
Viral Envelope Proteins | 1 | 2000 | 635 | 0.040 |
Why?
|
Acoustic Stimulation | 1 | 2021 | 1216 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3391 | 0.040 |
Why?
|
DNA Mutational Analysis | 2 | 2007 | 4187 | 0.040 |
Why?
|
Aged | 10 | 2021 | 162944 | 0.030 |
Why?
|
Erythrocytes | 1 | 2005 | 2452 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7770 | 0.030 |
Why?
|
HIV Antigens | 1 | 1996 | 347 | 0.030 |
Why?
|
Cytomegalovirus Infections | 1 | 2002 | 817 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2020 | 2257 | 0.030 |
Why?
|
Stochastic Processes | 1 | 1996 | 344 | 0.030 |
Why?
|
Cognition | 2 | 2012 | 6722 | 0.030 |
Why?
|
Age Factors | 3 | 2021 | 18355 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 2017 | 644 | 0.030 |
Why?
|
United Nations | 1 | 2016 | 165 | 0.030 |
Why?
|
Virus Cultivation | 1 | 1995 | 92 | 0.030 |
Why?
|
Exercise Tolerance | 1 | 2000 | 770 | 0.030 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2017 | 425 | 0.030 |
Why?
|
Muscles | 1 | 2020 | 1617 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2020 | 636 | 0.030 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2006 | 2211 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2001 | 1320 | 0.030 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 783 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2030 | 0.030 |
Why?
|
Population Density | 1 | 2014 | 194 | 0.030 |
Why?
|
Genes, env | 1 | 2013 | 95 | 0.030 |
Why?
|
Epidemiologic Methods | 2 | 1989 | 1364 | 0.030 |
Why?
|
Awareness | 1 | 2018 | 639 | 0.030 |
Why?
|
Sulfonamides | 2 | 2002 | 1932 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1048 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1215 | 0.030 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1994 | 247 | 0.030 |
Why?
|
Perioperative Care | 1 | 2000 | 997 | 0.030 |
Why?
|
Child | 4 | 2020 | 77478 | 0.030 |
Why?
|
Hawaii | 1 | 2011 | 104 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8328 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2018 | 1520 | 0.020 |
Why?
|
Placebos | 2 | 1993 | 1677 | 0.020 |
Why?
|
Blood Coagulation | 1 | 2017 | 1126 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2006 | 4249 | 0.020 |
Why?
|
Americas | 1 | 2010 | 111 | 0.020 |
Why?
|
Community Health Services | 1 | 2016 | 650 | 0.020 |
Why?
|
Infant | 3 | 2020 | 35070 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2021 | 57683 | 0.020 |
Why?
|
Data Collection | 3 | 2003 | 3339 | 0.020 |
Why?
|
Goals | 1 | 2016 | 705 | 0.020 |
Why?
|
South America | 1 | 2010 | 181 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1335 | 0.020 |
Why?
|
Florida | 1 | 2011 | 435 | 0.020 |
Why?
|
Caribbean Region | 1 | 2010 | 194 | 0.020 |
Why?
|
Disclosure | 1 | 2016 | 736 | 0.020 |
Why?
|
Health Education | 2 | 1988 | 1053 | 0.020 |
Why?
|
Child, Preschool | 3 | 2020 | 40955 | 0.020 |
Why?
|
Leg | 1 | 2015 | 1110 | 0.020 |
Why?
|
Quality Control | 1 | 2012 | 841 | 0.020 |
Why?
|
Furans | 2 | 2002 | 194 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15530 | 0.020 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2011 | 392 | 0.020 |
Why?
|
Carbamates | 2 | 2002 | 195 | 0.020 |
Why?
|
Brain | 2 | 2013 | 26343 | 0.020 |
Why?
|
Acute Disease | 2 | 2012 | 7141 | 0.020 |
Why?
|
Asia | 1 | 2010 | 607 | 0.020 |
Why?
|
Africa | 1 | 2010 | 670 | 0.020 |
Why?
|
Nerve Fibers | 1 | 2012 | 688 | 0.020 |
Why?
|
Death | 1 | 1993 | 675 | 0.020 |
Why?
|
Quality of Life | 2 | 2020 | 12730 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2012 | 598 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2012 | 6974 | 0.020 |
Why?
|
Africa, Southern | 1 | 2007 | 57 | 0.020 |
Why?
|
Drug Tolerance | 1 | 2009 | 375 | 0.020 |
Why?
|
HIV Reverse Transcriptase | 1 | 2008 | 213 | 0.020 |
Why?
|
Family Planning Services | 1 | 2010 | 258 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2004 | 7276 | 0.020 |
Why?
|
Heart Diseases | 1 | 2000 | 2789 | 0.020 |
Why?
|
Lactates | 1 | 2007 | 432 | 0.020 |
Why?
|
Factor VIII | 1 | 1989 | 348 | 0.020 |
Why?
|
Sex Distribution | 1 | 2012 | 2295 | 0.020 |
Why?
|
Genes, Viral | 1 | 2008 | 718 | 0.020 |
Why?
|
Arteries | 1 | 2011 | 1118 | 0.020 |
Why?
|
Contraceptive Devices | 1 | 1986 | 24 | 0.020 |
Why?
|
Government Programs | 1 | 2008 | 275 | 0.020 |
Why?
|
Drug Combinations | 1 | 2011 | 1961 | 0.020 |
Why?
|
Italy | 2 | 2001 | 828 | 0.020 |
Why?
|
Sexuality | 1 | 1988 | 174 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2017 | 3769 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10372 | 0.020 |
Why?
|
Case-Control Studies | 5 | 2006 | 21719 | 0.020 |
Why?
|
Institutionalization | 1 | 1986 | 104 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2017 | 3766 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2049 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2020 | 4229 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2013 | 1477 | 0.020 |
Why?
|
Mexico | 2 | 2000 | 688 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3862 | 0.010 |
Why?
|
Blood Donors | 1 | 1986 | 355 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2005 | 419 | 0.010 |
Why?
|
Base Sequence | 1 | 2014 | 12797 | 0.010 |
Why?
|
Public Policy | 1 | 1988 | 572 | 0.010 |
Why?
|
HIV Antibodies | 2 | 1988 | 1320 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2970 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81045 | 0.010 |
Why?
|
Licensure | 1 | 2003 | 124 | 0.010 |
Why?
|
Japan | 1 | 2006 | 1360 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2012 | 3760 | 0.010 |
Why?
|
Osteosarcoma | 1 | 2008 | 880 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3236 | 0.010 |
Why?
|
Skin | 1 | 2015 | 4353 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2005 | 676 | 0.010 |
Why?
|
Patient-Centered Care | 1 | 2011 | 1436 | 0.010 |
Why?
|
Europe | 1 | 2008 | 3339 | 0.010 |
Why?
|
Suburban Population | 1 | 1981 | 55 | 0.010 |
Why?
|
Mutation, Missense | 1 | 2010 | 2556 | 0.010 |
Why?
|
Animals | 3 | 2020 | 168561 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10232 | 0.010 |
Why?
|
Infant, Newborn | 2 | 1999 | 25575 | 0.010 |
Why?
|
Polymerase Chain Reaction | 2 | 2002 | 6171 | 0.010 |
Why?
|
Program Evaluation | 1 | 2008 | 2485 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2017 | 5169 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2004 | 1866 | 0.010 |
Why?
|
Cytokines | 1 | 2013 | 7317 | 0.010 |
Why?
|
Immunization Schedule | 1 | 1999 | 221 | 0.010 |
Why?
|
Developing Countries | 1 | 2010 | 2789 | 0.010 |
Why?
|
Hemoglobins | 1 | 2004 | 1532 | 0.010 |
Why?
|
Selection Bias | 1 | 2000 | 369 | 0.010 |
Why?
|
Proviruses | 1 | 1999 | 316 | 0.010 |
Why?
|
Drug Resistance, Multiple | 1 | 1998 | 252 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2008 | 6891 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4751 | 0.010 |
Why?
|
Patient Selection | 1 | 2007 | 4214 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1986 | 3164 | 0.010 |
Why?
|
Body Mass Index | 1 | 2012 | 12695 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13655 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1458 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2004 | 5975 | 0.010 |
Why?
|
Neurons | 1 | 2012 | 9325 | 0.010 |
Why?
|
Kinetics | 1 | 2001 | 6474 | 0.010 |
Why?
|
Hemophilia B | 1 | 1993 | 81 | 0.010 |
Why?
|
France | 1 | 1993 | 517 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 1992 | 402 | 0.010 |
Why?
|
Safety | 1 | 1995 | 1185 | 0.010 |
Why?
|
Substance Abuse, Intravenous | 1 | 1994 | 522 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1999 | 6608 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1990 | 637 | 0.010 |
Why?
|
Decision Making | 1 | 2003 | 3869 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 1995 | 1835 | 0.000 |
Why?
|
Age of Onset | 1 | 1994 | 3266 | 0.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 11472 | 0.000 |
Why?
|
New York City | 1 | 1988 | 706 | 0.000 |
Why?
|
New York | 1 | 1988 | 886 | 0.000 |
Why?
|
Recurrence | 1 | 1998 | 8333 | 0.000 |
Why?
|
Coronary Disease | 1 | 1981 | 6078 | 0.000 |
Why?
|
Forecasting | 1 | 1992 | 2948 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 1997 | 14720 | 0.000 |
Why?
|